Laith J Abu-Raddad1,2,3,4, Hiam Chemaitelly1,2, Houssein H Ayoub5, Hadi M Yassine6,7, Fatiha M Benslimane6,7, Hebah A Al Khatib6,7, Patrick Tang8, Mohammad R Hasan8, Peter Coyle6,9,10, Zaina Al Kanaani9, Einas Al Kuwari9, Andrew Jeremijenko9, Anvar Hassan Kaleeckal9, Ali Nizar Latif9, Riyazuddin Mohammad Shaik9, Hanan F Abdul Rahim11, Gheyath K Nasrallah6,7, Mohamed Ghaith Al Kuwari12, Adeel A Butt3,9, Hamad Eid Al Romaihi13, Mohamed H Al-Thani13, Abdullatif Al Khal9, Roberto Bertollini13. 1. Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. 2. World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar. 3. Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York. 4. Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar. 5. Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar. 6. Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar. 7. Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar. 8. Department of Pathology, Sidra Medicine, Doha, Qatar. 9. Hamad Medical Corporation, Doha, Qatar. 10. Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom. 11. College of Health Sciences, QU Health, Qatar University, Doha, Qatar. 12. Primary Health Care Corporation, Doha, Qatar. 13. Ministry of Public Health, Doha, Qatar.
Abstract
Importance: The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly understood. Objective: To assess protection from SARS-CoV-2 breakthrough infection after mRNA vaccination among persons with vs without prior SARS-CoV-2 infection. Design, Setting, and Participants: Matched-cohort studies in Qatar for the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines. A total of 1 531 736 individuals vaccinated with either vaccine between December 21, 2020, and September 19, 2021, were followed up beginning 14 days after receiving the second dose until September 19, 2021. Exposures: Prior SARS-CoV-2 infection and COVID-19 vaccination. Main Outcomes and Measures: Incident SARS-CoV-2 infection, defined as a polymerase chain reaction (PCR)-positive nasopharyngeal swab regardless of reason for PCR testing or presence of symptoms. Cumulative incidence was calculated using the Kaplan-Meier estimator method. Results: The BNT162b2-vaccinated cohort comprised 99 226 individuals with and 290 432 matched individuals without prior PCR-confirmed infection (median age, 37 years; 68% male). The mRNA-1273-vaccinated cohort comprised 58 096 individuals with and 169 514 matched individuals without prior PCR-confirmed infection (median age, 36 years; 73% male). Among BNT162b2-vaccinated persons, 159 reinfections occurred in those with and 2509 in those without prior infection 14 days or more after dose 2. Among mRNA-1273-vaccinated persons, 43 reinfections occurred in those with and 368 infections in those without prior infection. Cumulative infection incidence among BNT162b2-vaccinated individuals was an estimated 0.15% (95% CI, 0.12%-0.18%) in those with and 0.83% (95% CI, 0.79%-0.87%) in those without prior infection at 120 days of follow-up (adjusted hazard ratio for breakthrough infection with prior infection, 0.18 [95% CI, 0.15-0.21]; P < .001). Cumulative infection incidence among mRNA-1273-vaccinated individuals was an estimated 0.11% (95% CI, 0.08%-0.15%) in those with and 0.35% (95% CI, 0.32%-0.40%) in those without prior infection at 120 days of follow-up (adjusted hazard ratio, 0.35 [95% CI, 0.25-0.48]; P < .001). Vaccinated individuals with prior infection 6 months or more before dose 1 had statistically significantly lower risk for breakthrough infection than those vaccinated less than 6 months before dose 1 (adjusted hazard ratio, 0.62 [95% CI, 0.42-0.92]; P = .02 for BNT162b2 and 0.40 [95% CI, 0.18-0.91]; P = .03 for mRNA-1273 vaccination). Conclusions and Relevance: Prior SARS-CoV-2 infection was associated with a statistically significantly lower risk for breakthrough infection among individuals receiving the BNT162b2 or mRNA-1273 vaccines in Qatar between December 21, 2020, and September 19, 2021. The observational study design precludes direct comparisons of infection risk between the 2 vaccines.
Importance: The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly understood. Objective: To assess protection from SARS-CoV-2 breakthrough infection after mRNA vaccination among persons with vs without prior SARS-CoV-2 infection. Design, Setting, and Participants: Matched-cohort studies in Qatar for the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines. A total of 1 531 736 individuals vaccinated with either vaccine between December 21, 2020, and September 19, 2021, were followed up beginning 14 days after receiving the second dose until September 19, 2021. Exposures: Prior SARS-CoV-2 infection and COVID-19 vaccination. Main Outcomes and Measures: Incident SARS-CoV-2 infection, defined as a polymerase chain reaction (PCR)-positive nasopharyngeal swab regardless of reason for PCR testing or presence of symptoms. Cumulative incidence was calculated using the Kaplan-Meier estimator method. Results: The BNT162b2-vaccinated cohort comprised 99 226 individuals with and 290 432 matched individuals without prior PCR-confirmed infection (median age, 37 years; 68% male). The mRNA-1273-vaccinated cohort comprised 58 096 individuals with and 169 514 matched individuals without prior PCR-confirmed infection (median age, 36 years; 73% male). Among BNT162b2-vaccinated persons, 159 reinfections occurred in those with and 2509 in those without prior infection 14 days or more after dose 2. Among mRNA-1273-vaccinated persons, 43 reinfections occurred in those with and 368 infections in those without prior infection. Cumulative infection incidence among BNT162b2-vaccinated individuals was an estimated 0.15% (95% CI, 0.12%-0.18%) in those with and 0.83% (95% CI, 0.79%-0.87%) in those without prior infection at 120 days of follow-up (adjusted hazard ratio for breakthrough infection with prior infection, 0.18 [95% CI, 0.15-0.21]; P < .001). Cumulative infection incidence among mRNA-1273-vaccinated individuals was an estimated 0.11% (95% CI, 0.08%-0.15%) in those with and 0.35% (95% CI, 0.32%-0.40%) in those without prior infection at 120 days of follow-up (adjusted hazard ratio, 0.35 [95% CI, 0.25-0.48]; P < .001). Vaccinated individuals with prior infection 6 months or more before dose 1 had statistically significantly lower risk for breakthrough infection than those vaccinated less than 6 months before dose 1 (adjusted hazard ratio, 0.62 [95% CI, 0.42-0.92]; P = .02 for BNT162b2 and 0.40 [95% CI, 0.18-0.91]; P = .03 for mRNA-1273 vaccination). Conclusions and Relevance: Prior SARS-CoV-2 infection was associated with a statistically significantly lower risk for breakthrough infection among individuals receiving the BNT162b2 or mRNA-1273 vaccines in Qatar between December 21, 2020, and September 19, 2021. The observational study design precludes direct comparisons of infection risk between the 2 vaccines.
Authors: Laith J Abu-Raddad; Hiam Chemaitelly; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al Khatib; Patrick Tang; Joel A Malek; Peter Coyle; Houssein H Ayoub; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Abdullatif Al Khal; Adeel A Butt; Roberto Bertollini Journal: J Travel Med Date: 2021-05-28 Impact factor: 8.490
Authors: Mohamed H Al-Thani; Elmoubasher Farag; Roberto Bertollini; Hamad Eid Al Romaihi; Sami Abdeen; Ashraf Abdelkarim; Faisal Daraan; Ahmed Ibrahim Hashim Elhaj Ismail; Nahid Mostafa; Mohamed Sahl; Jinan Suliman; Elias Tayar; Hasan Ali Kasem; Meynard J A Agsalog; Bassam K Akkarathodiyil; Ayat A Alkhalaf; Mohamed Morhaf M H Alakshar; Abdulsalam Ali A H Al-Qahtani; Monther H A Al-Shedifat; Anas Ansari; Ahmad Ali Ataalla; Sandeep Chougule; Abhilash K K V Gopinathan; Feroz J Poolakundan; Sanjay U Ranbhise; Saed M A Saefan; Mohamed M Thaivalappil; Abubacker S Thoyalil; Inayath M Umar; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Adeel A Butt; Peter Coyle; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Hadi M Yassine; Gheyath K Nasrallah; Mohamed Ghaith Al Kuwari; Odette Chaghoury; Hiam Chemaitelly; Laith J Abu-Raddad Journal: Open Forum Infect Dis Date: 2021-05-02 Impact factor: 3.835
Authors: Hiam Chemaitelly; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al Khatib; Patrick Tang; Mohammad R Hasan; Joel A Malek; Peter Coyle; Houssein H Ayoub; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Abdullatif Al Khal; Adeel A Butt; Roberto Bertollini; Laith J Abu-Raddad Journal: Nat Med Date: 2021-07-09 Impact factor: 53.440
Authors: Mohammad R Hasan; Mahesh K R Kalikiri; Faheem Mirza; Sathyavathi Sundararaju; Anju Sharma; Thabisile Xaba; Stephan Lorenz; Hiam Chemaitelly; Reham A El-Kahlout; Kin Ming Tsui; Hadi M Yassine; Peter V Coyle; Abdullatif Al Khal; Roberto Bertollini; Mohamed H Al Thani; Laith J Abu-Raddad; Patrick Tang Journal: Int J Infect Dis Date: 2021-09-12 Impact factor: 3.623
Authors: Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber Journal: N Engl J Med Date: 2020-12-10 Impact factor: 91.245
Authors: Houssein H Ayoub; Hiam Chemaitelly; Shaheen Seedat; Monia Makhoul; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Adeel A Butt; Peter Coyle; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan Abdul Rahim; Hadi M Yassine; Mohamed G Al Kuwari; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Roberto Bertollini; Laith J Abu Raddad Journal: J Glob Health Date: 2021-01-16 Impact factor: 4.413
Authors: Catherine J Reynolds; Corinna Pade; Joseph M Gibbons; Áine McKnight; Daniel M Altmann; Rosemary Boyton; David K Butler; Ashley D Otter; Katia Menacho; Marianna Fontana; Angelique Smit; Jane E Sackville-West; Teresa Cutino-Moguel; Mala K Maini; Benjamin Chain; Mahdad Noursadeghi; Tim Brooks; Amanda Semper; Charlotte Manisty; Thomas A Treibel; James C Moon; Ana M Valdes Journal: Science Date: 2021-04-30 Impact factor: 63.714
Authors: Hiam Chemaitelly; Patrick Tang; Mohammad R Hasan; Sawsan AlMukdad; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al Khatib; Peter Coyle; Houssein H Ayoub; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar H Kaleeckal; Ali N Latif; Riyazuddin M Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Mohamed G Al Kuwari; Hamad E Al Romaihi; Adeel A Butt; Mohamed H Al-Thani; Abdullatif Al Khal; Roberto Bertollini; Laith J Abu-Raddad Journal: N Engl J Med Date: 2021-10-06 Impact factor: 91.245
Authors: Merryn Voysey; Sue Ann Costa Clemens; Shabir A Madhi; Lily Y Weckx; Pedro M Folegatti; Parvinder K Aley; Brian Angus; Vicky L Baillie; Shaun L Barnabas; Qasim E Bhorat; Sagida Bibi; Carmen Briner; Paola Cicconi; Elizabeth A Clutterbuck; Andrea M Collins; Clare L Cutland; Thomas C Darton; Keertan Dheda; Christina Dold; Christopher J A Duncan; Katherine R W Emary; Katie J Ewer; Amy Flaxman; Lee Fairlie; Saul N Faust; Shuo Feng; Daniela M Ferreira; Adam Finn; Eva Galiza; Anna L Goodman; Catherine M Green; Christopher A Green; Melanie Greenland; Catherine Hill; Helen C Hill; Ian Hirsch; Alane Izu; Daniel Jenkin; Carina C D Joe; Simon Kerridge; Anthonet Koen; Gaurav Kwatra; Rajeka Lazarus; Vincenzo Libri; Patrick J Lillie; Natalie G Marchevsky; Richard P Marshall; Ana V A Mendes; Eveline P Milan; Angela M Minassian; Alastair McGregor; Yama F Mujadidi; Anusha Nana; Sherman D Padayachee; Daniel J Phillips; Ana Pittella; Emma Plested; Katrina M Pollock; Maheshi N Ramasamy; Adam J Ritchie; Hannah Robinson; Alexandre V Schwarzbold; Andrew Smith; Rinn Song; Matthew D Snape; Eduardo Sprinz; Rebecca K Sutherland; Emma C Thomson; M Estée Török; Mark Toshner; David P J Turner; Johan Vekemans; Tonya L Villafana; Thomas White; Christopher J Williams; Alexander D Douglas; Adrian V S Hill; Teresa Lambe; Sarah C Gilbert; Andrew J Pollard Journal: Lancet Date: 2021-02-19 Impact factor: 79.321
Authors: Bram Decru; Jan Van Elslande; Sophie Steels; Gijs Van Pottelbergh; Lode Godderis; Bram Van Holm; Xavier Bossuyt; Johan Van Weyenbergh; Piet Maes; Pieter Vermeersch Journal: Front Immunol Date: 2022-06-15 Impact factor: 8.786
Authors: Duaa W Al-Sadeq; Farah M Shurrab; Ahmed Ismail; Fathima Humaira Amanullah; Swapna Thomas; Nader Aldewik; Hadi M Yassine; Hanan F Abdul Rahim; Laith Abu-Raddad; Gheyath K Nasrallah Journal: J Travel Med Date: 2021-12-29 Impact factor: 8.490
Authors: Jesús Fernando García-Cruces-Méndez; Luis Corral-Gudino; María Piedad Del-Amo-Merino; José María Eiros-Bouza; Marta Domínguez-Gil González Journal: Eur J Intern Med Date: 2022-01-05 Impact factor: 4.487
Authors: Laith J Abu-Raddad; Hiam Chemaitelly; Houssein H Ayoub; Patrick Tang; Peter Coyle; Mohammad R Hasan; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al-Khatib; Zaina Al-Kanaani; Einas Al-Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul-Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al-Kuwari; Adeel A Butt; Hamad Eid Al-Romaihi; Abdullatif Al-Khal; Mohametabd H Al-Thani; Roberto Bertollini Journal: Nat Commun Date: 2022-01-27 Impact factor: 14.919
Authors: Marek Petráš; Ivana Králová Lesná; Livia Večeřová; Elka Nyčová; Jana Malinová; Petr Klézl; Martina Nezvedová; Rachel Elizabeth White; Roman Máčalík; Jana Dáňová; Alexander M Čelko; Věra Adámková Journal: Vaccines (Basel) Date: 2021-12-22